审议通过《关于修订公司部分制度的议案》 本议案采用逐项表决方式，具体表决情况如下： 华东医药股份有限公司 第十届董事会独立董事专门会议 2025 年第二次会议决议 华东医药股份有限公司（以下简称"公司"）第十届董事会独立董 事专门会议 2025 年第二次会议于 2025 年 06 月 27 日（星期五）在公 司会议室以通讯的方式召开。会议通知已于 2025 年 06 月 24 日通过 邮件的方式送达各位独立董事。本次会议应出席独立董事 3 人，实际 出席独立董事 3 人。 会议由全体独立董事共同推举黄简女士担任召集人和主持人。会 议召开符合有关法律、法规、规章和《公司章程》《独立董事工作制 度》的规定。经各位独立董事认真审议，会议形成了如下决议： 1.01《关于修订<独立董事工作制度>的议案》； 表决结果：3票同意，0票反对，0票弃权。 1.02《关于修订<关联交易管理制度>的议案》； 表决结果：3 票同意，0 票反对，0 票弃权。 经认真审阅，基于独立判断，我们认为：公司根据《中华人民共 和国公司法》《深圳证券交易所股票上市规则（2025 年修订）》《深 圳证券交易所上市公司自律监管指引第 1 号——主板上 ...

证券代码：000963 证券简称：华东医药 公告编号：2025-048 华东医药股份有限公司 第十届董事会第三十四次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 华东医药股份有限公司（以下简称"公司"）第十届董事会第三 十四次会议的通知于2025年06月24日以书面和电子邮件等方式送达 各位董事，于2025年06月27日（星期五）在公司会议室以现场并结合 通讯方式召开。会议应参加董事9名，实际参加董事9名。会议由公司 董事长主持。会议的召开和表决程序符合《公司法》《公司章程》的 有关规定，会议合法有效。 二、董事会会议审议情况 董事会就以下议案进行了审议，经书面和通讯方式表决，通过决 议如下： （一）审议通过《关于调整2022年限制性股票激励计划回购价格 的议案》 具体内容详见公司同日披露于巨潮资讯网（www.cninfo.com.cn） 的公司《关于调整2022年限制性股票激励计划回购价格的公告》。 表决结果：9票同意，0票反对，0票弃权。 该议案已经公司第十届董事会薪酬与考核委员会2025年第二次 会议审议通过。 1 ...

Core Insights - The biopharmaceutical industry in China has significant growth potential, driven by a series of supportive policies aimed at promoting innovative drug development [1][2] - Companies in the Shenzhen market are focusing on independent innovation to explore new frontiers in life and health, contributing to the global pharmaceutical innovation landscape [1][2] Policy Support - The Chinese government has intensified support for the innovative drug industry, with a comprehensive policy framework established in July 2024 to enhance various aspects such as pricing management, insurance payments, and clinical trial approvals [2] - Local governments are also actively promoting the development of innovative drugs, exemplified by Beijing's plan for high-quality construction of an international pharmaceutical innovation park from 2025 to 2030 [2] Company Developments - Huadong Medicine (000963) has 133 ongoing pharmaceutical projects, with 94 focused on innovative drugs and biosimilars, including a diverse range of drug types targeting various diseases [3][5] - Haizhu Pharmaceutical (002653) has 14 innovative drug products in clinical stages, emphasizing its commitment to becoming a trusted international pharmaceutical company [3] - Betta Pharmaceuticals (300558) has over 20 years of experience in cancer drug innovation and is focused on developing proprietary drugs [3] Financial Performance - Huadong Medicine reported a 16.77% increase in R&D investment to 2.678 billion yuan in 2024, with direct R&D expenses accounting for 12.91% of its pharmaceutical revenue [5][6] - Haizhu Pharmaceutical's revenue reached 3.721 billion yuan in 2024, a 10.92% increase, with a net profit of 395 million yuan, reflecting a 34% growth [6] - Betta Pharmaceuticals achieved a revenue of 2.892 billion yuan in 2024, marking a 17.74% increase, with a net profit growth of 55.92% [7]

Core Viewpoint - The pharmaceutical industry in Shenzhen is experiencing unprecedented development opportunities driven by continuous national policy support, with companies like Haizhi Pharmaceutical Group making significant progress in innovative drug development [1][3]. Policy Support and Industry Growth - The national government has enhanced support for the innovative drug industry, establishing a multi-dimensional policy framework that significantly reduces the time for innovative drugs to reach the market [3]. - The establishment of a dynamic adjustment mechanism for the medical insurance catalog has created a green channel for innovative drugs, accelerating the translation of innovative results into clinical applications [3]. - Local governments are also actively responding to national strategies, exemplified by Beijing's plan for the International Pharmaceutical Innovation Park, which aims to provide comprehensive services and expedite product registration processes for innovative drugs [3]. Company Innovations and Achievements - Shenzhen's innovative pharmaceutical companies have made remarkable breakthroughs, with Huadong Medicine developing a product matrix in key areas such as autoimmune diseases and oncology, successfully launching multiple innovative drugs that are now included in the medical insurance catalog [3]. - Betta Pharmaceuticals has established a complete product line targeting key lung cancer markers and is expanding into other therapeutic areas, demonstrating a long-term commitment to oncology innovation [3]. Challenges in Drug Development - Despite positive growth, Shenzhen's innovative pharmaceutical companies face significant challenges, including the complexity of the R&D process, high costs, and low success rates in clinical trials [4]. - The average time for innovative drug development is between 10 to 15 years, with a clinical trial failure rate exceeding 90%, creating substantial financial pressure on companies [4]. - There is a notable shortage of high-end interdisciplinary R&D talent, leading to high training costs and difficulties in fundraising due to the high-risk nature of innovative drug development [4]. Strategic Responses to Challenges - Companies are seeking breakthroughs through differentiated strategies, international expansion, and technological innovation, with Huadong Medicine completing over 30 business development collaborations in the past five years to enhance its R&D capabilities [4][5]. - Betta Pharmaceuticals is focusing on building an innovation ecosystem based on collaboration and shared resources, aiming to foster interaction among talent, projects, information, and funding [5]. - The industry is demonstrating a proactive approach to challenges, emphasizing the importance of innovation and transformation to secure a position in the global pharmaceutical landscape [5].

Investment Rating - The report indicates a strong growth trajectory for the GLP-1RA market, with an expected market size of 71.7 billion yuan by 2029, reflecting a compound annual growth rate (CAGR) of 22.2% from 2023 [4][7]. Core Insights - GLP-1 receptor agonists (GLP-1RA) have become core therapeutic agents in the treatment of metabolic diseases due to their multifaceted pharmacological effects, including glycemic control, weight management, and cardiovascular protection [4]. - The market is characterized by intense competition, with multinational pharmaceutical companies holding a dominant position while domestic firms rapidly advance through local resources and policy support [4][8]. - The demand for GLP-1RA is driven by the rising prevalence of metabolic diseases, particularly diabetes and obesity, alongside increasing patient awareness and clinical application [8][10]. Market Background - GLP-1RA drugs are defined as medications that mimic the action of glucagon-like peptide-1 (GLP-1) to regulate blood sugar, manage weight, and protect organs, available in short-acting, long-acting, and oral formulations [5]. - The market has evolved significantly since the approval of the first GLP-1RA in 2005, with a notable increase in long-acting formulations that enhance patient compliance and expand indications beyond diabetes to include obesity [6]. Market Status - The GLP-1RA market in China is projected to grow from 10.74 billion yuan in 2023 to 71.7 billion yuan by 2029, driven by a CAGR of 22.2% [7]. - The market is currently experiencing rapid development, with domestic companies accelerating the development of generic drugs as patents for leading products expire [9]. - The demand for GLP-1RA remains high, with a diabetes prevalence rate of 11.9% in China and a treatment rate of only 33%, indicating significant unmet clinical needs [10]. Market Competition - The competitive landscape is divided into three tiers: - The first tier includes multinational giants like Novo Nordisk and Eli Lilly, with Novo Nordisk leading the market due to the strong performance of semaglutide [14]. - The second tier consists of domestic leaders such as Huadong Medicine and Innovent Biologics, which are making strides with generic and innovative products [15]. - The third tier features innovative companies focusing on oral formulations and differentiated pipelines [15]. Development Trends - The trend towards multi-target drugs is accelerating, with innovations like dual-target agents showing over 30% improvement in efficacy compared to traditional single-target drugs [18]. - Breakthroughs in oral formulations are changing the market dynamics, with expectations that oral GLP-1RA will capture over 30% of the market share by 2028 [19]. - The expansion of indications for GLP-1RA is rapidly progressing, with ongoing research into applications for non-alcoholic fatty liver disease and Alzheimer's disease [20].

Group 1 - Hengbang Co., Ltd. plans to establish a joint venture with Huasheng Development with a registered capital of 10 million yuan, where Hengbang will contribute 8 million yuan (80%) and Huasheng will contribute 2 million yuan (20%) [1] - Hunan Gold's subsidiary Anhua Zhazi Creek Smelting Plant will undergo temporary maintenance starting from the end of June 2025, expected to last no more than 30 days [2] - Defu Technology's subsidiary signed supply agreements for lithium battery copper foil products with two leading global companies, with contract durations of 3 years and 5 years respectively [3] Group 2 - Binjiang Group won the rights to two residential land parcels for a total price of 4.368 billion yuan [5] - Zhong'an Technology announced the resignation of its executive vice president and board secretary due to personal reasons [7] - Changqing Technology's project for special polymer materials and electronic materials has officially commenced production, adding a capacity of 120,500 tons per year [10] Group 3 - Gansu Energy received approval from the China Securities Regulatory Commission to publicly issue bonds totaling up to 2 billion yuan [10] - Shuoshi Biology obtained a medical device registration certificate for an in vitro diagnostic reagent, valid until June 2030 [12] - Yawen Co., Ltd. plans to issue shares to specific investors, with the application accepted by the Shenzhen Stock Exchange [13] Group 4 - Guoyao Modern's subsidiary received approval for the listing of a raw material drug, which is a selective anticholinergic agent [16] - Inner Mongolia First Machinery's subsidiary signed a railway freight car procurement contract worth 130 million yuan [18] - Xining Special Steel plans to raise up to 1 billion yuan through a private placement to its controlling shareholder [39] Group 5 - Huadong Medicine's subsidiary received approval for a clinical trial of a new injectable drug targeting advanced solid tumors [29] - Warner Pharmaceutical's compound potassium hydrogen phosphate injection passed the consistency evaluation for generic drugs [30] - North Special Technology plans to raise up to 300 million yuan through a private placement for a production base project in Thailand [30] Group 6 - Xiangyang Technology is the first candidate for a 533 million yuan Airbus project [45] - Haishun New Materials intends to acquire 100% of Guangdong Zhengyi Packaging [46] - Jida Zhengyuan's shareholder plans to reduce their stake by up to 0.73% due to personal financial needs [47]

关于全资子公司获得药物临床试验批准通知书的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 2025 年 06 月 25 日，华东医药股份有限公司（以下简称"公司"） 全资子公司杭州中美华东制药有限公司（以下简称"中美华东"）收到 国家药品监督管理局（NMPA）核准签发的《药物临床试验批准通知 书》（通知书编号：2025LP01647），由中美华东申报的注射用HDM2020 临床试验申请获得批准，现将有关详情公告如下： 一、该药物基本信息 药物名称：注射用 HDM2020 证券代码：000963 证券简称：华东医药 公告编号：2025-047 华东医药股份有限公司 注册分类：治疗用生物制品 1 类 受理号：CXSL2500317 适应症：晚期实体瘤 申请事项：临床试验 申请人：杭州中美华东制药有限公司 结论：根据《中华人民共和国药品管理法》及有关规定，经审查， 2025 年 4 月 17 日受理的注射用 HDM2020 临床试验申请符合药品注 册的有关要求，同意本品开展晚期实体瘤的临床试验。 二、该药物研发及注册情况 注射用 HDM2020 是由中美华东研 ...

Core Viewpoint - The approval of clinical trials for HDM2020 marks a significant milestone in the development of a new targeted antibody-drug conjugate aimed at treating advanced solid tumors, enhancing the company's competitiveness in the oncology treatment sector [1] Company Summary - Huadong Medicine's wholly-owned subsidiary, Sino-American Huadong, received the Clinical Trial Approval Notice from the National Medical Products Administration for HDM2020 [1] - HDM2020 targets fibroblast growth factor receptor 2b and has demonstrated significant anti-tumor activity in preclinical studies [1] - The company plans to continue advancing drug development and will disclose information based on progress [1] Industry Summary - The approval of HDM2020 for clinical trials reflects ongoing innovation in the oncology treatment field, particularly in the development of targeted therapies [1] - The successful development and potential commercialization of HDM2020 could position the company favorably within the competitive landscape of cancer therapeutics [1]

Core Insights - The article discusses the emergence of Ecnoglutide, a new GLP-1 receptor agonist developed by a team led by Professor Ji Linong from Peking University People's Hospital, which poses a challenge to the market dominance of Novo Nordisk's Semaglutide in the weight loss drug sector [1][4]. Company Developments - Ecnoglutide has shown impressive results in its Phase III clinical trial (SLIMMER), with over 92.8% of participants achieving effective weight loss and an average weight reduction of 15.1% over 48 weeks [3][4]. - The trial involved 664 participants across 36 centers in China, making it the largest sample size for a weight loss drug trial in the country [3]. - The drug has entered the market application stage, indicating a potential for commercialization soon [4]. Market Landscape - The global GLP-1 weight loss drug market is projected to exceed $150 billion by 2025, with Novo Nordisk's Semaglutide leading the market, generating $8 billion in Q1 2025, a 31% year-on-year increase [5]. - Other companies, including Hengrui Medicine, East China Pharmaceutical, and others, are actively developing weight loss drugs, with some products already in Phase II or III clinical trials [2][6]. Competitive Dynamics - Ecnoglutide's clinical trial results suggest a significant competitive edge over existing products, with a higher effective weight loss rate compared to similar drugs [3][4]. - The article highlights the potential for domestic companies to challenge established players like Novo Nordisk and Eli Lilly, as several innovative drugs are in advanced clinical stages [6]. Future Outlook - The article emphasizes the commercial opportunity for domestic alternatives in the weight loss drug market, especially as imported drugs have already cultivated market demand [7].

Group 1 - Company announced research results of three innovative GLP-1 drugs at the 85th American Diabetes Association (ADA) Scientific Sessions in 2025 [1] - The self-developed GLP-1/GIP dual-target long-acting agonist HDM1005 was selected for an oral presentation at the conference [1] - HDM1005 is undergoing Phase II clinical trials for weight management and is expected to enter Phase III trials in Q4 2025 [1] Group 2 - HDM1002 is a new oral non-peptide GLP-1 receptor agonist, with a Phase I clinical study focusing on safety, tolerability, pharmacokinetics, and pharmacodynamics in overweight or obese subjects [2] - The Phase III clinical study for weight management indication of HDM1002 has completed the first subject enrollment in April 2025 [2] - The submission for marketing approval of the semaglutide injection for diabetes indication was accepted in March 2025 [2] Group 3 - Company ranked 41st in the "2025 Global Pharmaceutical Companies Top 50" list published by Pharmaceutical Executive magazine, marking a historic high with six Chinese companies on the list [3] - This ranking reflects the company's enhanced comprehensive competitiveness and international recognition [3]